Author Archives: Natalie Themm
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024.
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
Myriad Genetics announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.
Ultradent Named a Fortune Magazine Top Workplace for Third Straight Year
Ultradent Products is being recognized for the third consecutive year as a Fortune Magazine Top Large Workplace in Manufacturing and Production.
BioTuesdays Features Halia Therapeutics CEO
In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]
BlueWind Medical’s Revi™ System Secures U.S. FDA De Novo Classification Grant for the Treatment of Urgency Incontinence
Revi redefines the treatment of Urgency Incontinence with a patient-centric implantable tibial neuromodulation solution that empowers patients
Inherent Biosciences, Inc. Advances Fertility Solutions With Transformative Grant Funding From the NIH
A Leap Forward for Patients, a Promising Opportunity for Investors, and a Revolutionary Tool for Physicians
This plan to cut drug prices could result in lost jobs and fewer medicines
By Kelvyn Cullimore For the Deseret News
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances were made possible by NVIDIA DGX Cloud supercomputing and the recent acquisition of Cyclica’s MatchMaker technology.
Utah Company Developing Origami-inspired Technology Awarded NSF Grant to Advance Robotic Surgery
August 7, 2023 Four years ago, Jacob Sheffield was building world-class carbon fiber travel guitars for adventurers journeying to places as remote as Everest and Antarctica. Ian Esplin was growing viruses in bioreactors and developing therapies to combat antibiotic-resistant pathogens. The two came together and co-founded Bloom Surgical with a goal to empower robotic surgeons […]
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
Myriad Genetics announced enhancements to the GeneSight® Psychotropic test.
